Wheeler, D.C.; Stefansson, B.V.; Batiushin, M.; Bilchenko, O.; Cherney, D.Z.I.; Chertow, G.M.; Douthat, W.; Dwyer, J.P.; Escudero, E.; Pecoits-Filho, R.; Furuland, H.; Górriz, J.L.; Greene, T.; Haller, H.; Hou, F.F.; Kang, S.-W.; Isidto, R.; Khullar, D.; Mark, P.B.; McMurray, J.J.V.; Kashihara, N.; Nowicki, M.; Persson, F.; Correa-Rotter, R.; Rossing, P.; Toto, R.D.; Umanath, K.; Van Bui, P.; Wittmann, I.; Lindberg, M.; Sjöström, C.D.; Langkilde, A.M.; Heerspink, H.J.L.
(Oxford University Press, 2020)
BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin ...
